Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Senhwa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2020
US National Institutes of Health (NIH) will evaluate the efficacy of Silmitasertib for treatment of COVID-19.